APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ischemia Reperfusion Injury

Reperfusion injury or reperfusion insult, sometimes called ischemia-reperfusion injury (IRI) or reoxygenation injury, is the tissue damage caused when blood supply returns to tissue (re- + perfusion) after a period of ischemia or lack of oxygen (anoxia or hypoxia). The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than (or along with) restoration of normal function.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Reperfusion injury or reperfusion insult, sometimes called ischemia-reperfusion injury (IRI) or reoxygenation injury, is the tissue damage caused when blood supply returns to tissue (re- + perfusion) after a period of ischemia or lack of oxygen (anoxia or hypoxia). The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than (or along with) restoration of normal function.

Selected research

Market Outlook & Growth Opportunities

Global Ischemia Reperfusion Injury Market Outlook and Growth Opportunities 2026

21 December 2025196 pages

Choose your research edition.

Industry ResearchIschemia Reperfusion Injury Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Ischemia Reperfusion Injury Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Ischemia Reperfusion Injury Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ischemia Reperfusion Injury Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Ischemia Reperfusion Injury Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Reperfusion injury or reperfusion insult, sometimes called ischemia-reperfusion injury (IRI) or reoxygenation injury, is the tissue damage caused when blood supply returns to tissue (re- + perfusion) after a period of ischemia or lack of oxygen (anoxia or hypoxia). The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than (or along with) restoration of normal function.

Global Ischemia Reperfusion Injury key players include Angion Biomedica, Catalyst Biosciences, Ischemix Inc, etc.

North America is the largest market, with a share about 50%, followed by Europe, and Japan, both have a share over 20 percent.

Read the full market overview

In terms of product, Phase 2 is the largest segment, with a share about 40%. And in terms of application, the largest application is Kidney Injury, followed by Heart Injury, Intestine Injury, etc.

This report provides an overview of the global Ischemia Reperfusion Injury market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Ischemia Reperfusion Injury and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Ischemia Reperfusion Injury revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Ischemia Reperfusion Injury market.

Ischemia Reperfusion Injury Segment by Company

Angion Biomedica

Catalyst Biosciences

Ischemix Inc

Opsona Therapeutics

Pharming

TheraSource

Bolder Biotechnology

Corline Biomedical

Mifcortx

Balmes Transplantation

NovelMed Therapeutics

Hope Pharmaceuticals

Omeros Corp

Prothix

SBI Pharmaceuticals

Ischemia Reperfusion Injury Segment by Type

Phase 1

Phase 2

Preclinical

Ischemia Reperfusion Injury Segment by Application

Heart Injury

Kidney Injury

Intestine Injury

Other Injury

Ischemia Reperfusion Injury Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Ischemia Reperfusion Injury status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Ischemia Reperfusion Injury key companies, revenue, market share, and recent developments.

3. To split the Ischemia Reperfusion Injury breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Ischemia Reperfusion Injury market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Ischemia Reperfusion Injury significant trends, drivers, influence factors in global and regions.

6. To analyze Ischemia Reperfusion Injury competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ischemia Reperfusion Injury market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ischemia Reperfusion Injury and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ischemia Reperfusion Injury.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ischemia Reperfusion Injury industry.

Chapter 3: Detailed analysis of Ischemia Reperfusion Injury company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Ischemia Reperfusion Injury in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Ischemia Reperfusion Injury in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Ischemia Reperfusion Injury Industry Trends Table 2. Ischemia Reperfusion Injury Industry Drivers Table 3. Ischemia Reperfusion Injury Industry Opportunities and Challenges Table 4. Ischemia Reperfusion Injury Industry Restraints Table 5. Global Ischemia Reperfusion Injury Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Ischemia Reperfusion Injury Revenue Share by Company (2021-2026) Table 7. Global Ischemia Reperfusion Injury Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Ischemia Reperfusion Injury Key Company Manufacturing Base & Headquarters Table 9. Global Ischemia Reperfusion Injury Company, Product Type & Application Table 10. Global Ischemia Reperfusion Injury Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Ischemia Reperfusion Injury by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Phase 1 Table 15. Significant Companies of Phase 2 Table 16. Significant Companies of Preclinical Table 17. Global Ischemia Reperfusion Injury Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Ischemia Reperfusion Injury Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Ischemia Reperfusion Injury Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Ischemia Reperfusion Injury Sales Value Share by Type (2021-2026) Table 21. Global Ischemia Reperfusion Injury Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Heart Injury Table 23. Significant Companies of Kidney Injury Table 24. Significant Companies of Intestine Injury Table 25. Significant Companies of Other Injury Table 26. Global Ischemia Reperfusion Injury Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Ischemia Reperfusion Injury Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Ischemia Reperfusion Injury Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Ischemia Reperfusion Injury Sales Value Share by Application (2021-2026) Table 30. Global Ischemia Reperfusion Injury Sales Value Share by Application (2027-2032) Table 31. Global Ischemia Reperfusion Injury Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Ischemia Reperfusion Injury Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Ischemia Reperfusion Injury Sales Value Share by Region (2021-2026) Table 34. Global Ischemia Reperfusion Injury Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Ischemia Reperfusion Injury Sales Value Share by Region (2027-2032) Table 36. Global Ischemia Reperfusion Injury Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Ischemia Reperfusion Injury Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Ischemia Reperfusion Injury Sales Value Market Share by Country (2021-2026) Table 39. Global Ischemia Reperfusion Injury Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Ischemia Reperfusion Injury Sales Value Market Share by Country (2027-2032) Table 41. Angion Biomedica Company Information Table 42. Angion Biomedica Business Overview Table 43. Angion Biomedica Ischemia Reperfusion Injury Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Angion Biomedica Ischemia Reperfusion Injury Product Portfolio Table 45. Angion Biomedica Recent Development Table 46. Catalyst Biosciences Company Information Table 47. Catalyst Biosciences Business Overview Table 48. Catalyst Biosciences Ischemia Reperfusion Injury Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Catalyst Biosciences Ischemia Reperfusion Injury Product Portfolio Table 50. Catalyst Biosciences Recent Development Table 51. Ischemix Inc Company Information Table 52. Ischemix Inc Business Overview Table 53. Ischemix Inc Ischemia Reperfusion Injury Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Ischemix Inc Ischemia Reperfusion Injury Product Portfolio Table 55. Ischemix Inc Recent Development Table 56. Opsona Therapeutics Company Information Table 57. Opsona Therapeutics Business Overview Table 58. Opsona Therapeutics Ischemia Reperfusion Injury Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Opsona Therapeutics Ischemia Reperfusion Injury Product Portfolio Table 60. Opsona Therapeutics Recent Development Table 61. Pharming Company Information Table 62. Pharming Business Overview Table 63. Pharming Ischemia Reperfusion Injury Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Pharming Ischemia Reperfusion Injury Product Portfolio Table 65. Pharming Recent Development Table 66. TheraSource Company Information Table 67. TheraSource Business Overview Table 68. TheraSource Ischemia Reperfusion Injury Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. TheraSource Ischemia Reperfusion Injury Product Portfolio Table 70. TheraSource Recent Development Table 71. Bolder Biotechnology Company Information Table 72. Bolder Biotechnology Business Overview Table 73. Bolder Biotechnology Ischemia Reperfusion Injury Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Bolder Biotechnology Ischemia Reperfusion Injury Product Portfolio Table 75. Bolder Biotechnology Recent Development Table 76. Corline Biomedical Company Information Table 77. Corline Biomedical Business Overview Table 78. Corline Biomedical Ischemia Reperfusion Injury Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Corline Biomedical Ischemia Reperfusion Injury Product Portfolio Table 80. Corline Biomedical Recent Development Table 81. Mifcortx Company Information Table 82. Mifcortx Business Overview Table 83. Mifcortx Ischemia Reperfusion Injury Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Mifcortx Ischemia Reperfusion Injury Product Portfolio Table 85. Mifcortx Recent Development Table 86. Balmes Transplantation Company Information Table 87. Balmes Transplantation Business Overview Table 88. Balmes Transplantation Ischemia Reperfusion Injury Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Balmes Transplantation Ischemia Reperfusion Injury Product Portfolio Table 90. Balmes Transplantation Recent Development Table 91. NovelMed Therapeutics Company Information Table 92. NovelMed Therapeutics Business Overview Table 93. NovelMed Therapeutics Ischemia Reperfusion Injury Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 94. NovelMed Therapeutics Ischemia Reperfusion Injury Product Portfolio Table 95. NovelMed Therapeutics Recent Development Table 96. Hope Pharmaceuticals Company Information Table 97. Hope Pharmaceuticals Business Overview Table 98. Hope Pharmaceuticals Ischemia Reperfusion Injury Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 99. Hope Pharmaceuticals Ischemia Reperfusion Injury Product Portfolio Table 100. Hope Pharmaceuticals Recent Development Table 101. Omeros Corp Company Information Table 102. Omeros Corp Business Overview Table 103. Omeros Corp Ischemia Reperfusion Injury Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 104. Omeros Corp Ischemia Reperfusion Injury Product Portfolio Table 105. Omeros Corp Recent Development Table 106. Prothix Company Information Table 107. Prothix Business Overview Table 108. Prothix Ischemia Reperfusion Injury Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 109. Prothix Ischemia Reperfusion Injury Product Portfolio Table 110. Prothix Recent Development Table 111. SBI Pharmaceuticals Company Information Table 112. SBI Pharmaceuticals Business Overview Table 113. SBI Pharmaceuticals Ischemia Reperfusion Injury Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 114. SBI Pharmaceuticals Ischemia Reperfusion Injury Product Portfolio Table 115. SBI Pharmaceuticals Recent Development Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Ischemia Reperfusion Injury Product Image Figure 2. Global Ischemia Reperfusion Injury Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ischemia Reperfusion Injury Market Size (2021-2032) & (US$ Million) Figure 4. Global Ischemia Reperfusion Injury Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Phase 1 Image Figure 8. Phase 2 Image Figure 9. Preclinical Image Figure 10. Global Ischemia Reperfusion Injury Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Ischemia Reperfusion Injury Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Ischemia Reperfusion Injury Sales Value Share by Type (2021-2032) Figure 13. Heart Injury Image Figure 14. Kidney Injury Image Figure 15. Intestine Injury Image Figure 16. Other Injury Image Figure 17. Global Ischemia Reperfusion Injury Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Ischemia Reperfusion Injury Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Ischemia Reperfusion Injury Sales Value Share by Application (2021-2032) Figure 20. Global Ischemia Reperfusion Injury Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Ischemia Reperfusion Injury Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Ischemia Reperfusion Injury Sales Value (2021-2032) & (US$ Million) Figure 23. North America Ischemia Reperfusion Injury Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Ischemia Reperfusion Injury Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Ischemia Reperfusion Injury Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Ischemia Reperfusion Injury Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Ischemia Reperfusion Injury Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Ischemia Reperfusion Injury Sales Value (2021-2032) & (US$ Million) Figure 29. South America Ischemia Reperfusion Injury Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Ischemia Reperfusion Injury Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Ischemia Reperfusion Injury Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Phase 1
  • Phase 2
  • Preclinical
Applications
  • Heart Injury
  • Kidney Injury
  • Intestine Injury
  • Other Injury
Companies covered
  • Angion Biomedica
  • Catalyst Biosciences
  • Ischemix Inc
  • Opsona Therapeutics
  • Pharming
  • TheraSource
  • Bolder Biotechnology
  • Corline Biomedical
  • Mifcortx
  • Balmes Transplantation
  • NovelMed Therapeutics
  • Hope Pharmaceuticals
  • Omeros Corp
  • Prothix
  • SBI Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Ischemia Reperfusion Injury Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Ischemia Reperfusion Injury Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Ischemia Reperfusion Injury Market Dynamics
  1. 2.1 Ischemia Reperfusion Injury Industry Trends
  2. 2.2 Ischemia Reperfusion Injury Industry Drivers
  3. 2.3 Ischemia Reperfusion Injury Industry Opportunities and Challenges
  4. 2.4 Ischemia Reperfusion Injury Industry Restraints
3 Ischemia Reperfusion Injury Market by Company
  1. 3.1 Global Ischemia Reperfusion Injury Company Revenue Ranking in 2025
  2. 3.2 Global Ischemia Reperfusion Injury Revenue by Company (2021-2026)
  3. 3.3 Global Ischemia Reperfusion Injury Company Ranking (2024-2026)
  4. 3.4 Global Ischemia Reperfusion Injury Company Manufacturing Base and Headquarters
  5. 3.5 Global Ischemia Reperfusion Injury Company Product Type and Application
  6. 3.6 Global Ischemia Reperfusion Injury Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Ischemia Reperfusion Injury Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Ischemia Reperfusion Injury Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Ischemia Reperfusion Injury Market by Type
  1. 4.1 Ischemia Reperfusion Injury Type Introduction
  2. 4.1.1 Phase 1
  3. 4.1.2 Phase 2
  4. 4.1.3 Preclinical
  5. 4.2 Global Ischemia Reperfusion Injury Sales Value by Type
  6. 4.2.1 Global Ischemia Reperfusion Injury Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Ischemia Reperfusion Injury Sales Value by Type (2021-2032)
  8. 4.2.3 Global Ischemia Reperfusion Injury Sales Value Share by Type (2021-2032)
5 Ischemia Reperfusion Injury Market by Application
  1. 5.1 Ischemia Reperfusion Injury Application Introduction
  2. 5.1.1 Heart Injury
  3. 5.1.2 Kidney Injury
  4. 5.1.3 Intestine Injury
  5. 5.1.4 Other Injury
  6. 5.2 Global Ischemia Reperfusion Injury Sales Value by Application
  7. 5.2.1 Global Ischemia Reperfusion Injury Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Ischemia Reperfusion Injury Sales Value by Application (2021-2032)
  9. 5.2.3 Global Ischemia Reperfusion Injury Sales Value Share by Application (2021-2032)
6 Ischemia Reperfusion Injury Regional Value Analysis
  1. 6.1 Global Ischemia Reperfusion Injury Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Ischemia Reperfusion Injury Sales Value by Region (2021-2032)
  3. 6.2.1 Global Ischemia Reperfusion Injury Sales Value by Region: 2021-2026
  4. 6.2.2 Global Ischemia Reperfusion Injury Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Ischemia Reperfusion Injury Sales Value (2021-2032)
  7. 6.3.2 North America Ischemia Reperfusion Injury Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Ischemia Reperfusion Injury Sales Value (2021-2032)
  10. 6.4.2 Europe Ischemia Reperfusion Injury Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Ischemia Reperfusion Injury Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Ischemia Reperfusion Injury Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Ischemia Reperfusion Injury Sales Value (2021-2032)
  16. 6.6.2 South America Ischemia Reperfusion Injury Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Ischemia Reperfusion Injury Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Ischemia Reperfusion Injury Sales Value Share by Country, 2025 VS 2032
7 Ischemia Reperfusion Injury Country-level Value Analysis
  1. 7.1 Global Ischemia Reperfusion Injury Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Ischemia Reperfusion Injury Sales Value by Country (2021-2032)
  3. 7.2.1 Global Ischemia Reperfusion Injury Sales Value by Country (2021-2026)
  4. 7.2.2 Global Ischemia Reperfusion Injury Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Ischemia Reperfusion Injury Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Ischemia Reperfusion Injury Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Ischemia Reperfusion Injury Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Angion Biomedica
  2. 8.1.1 Angion Biomedica Company Information
  3. 8.1.2 Angion Biomedica Business Overview
  4. 8.1.3 Angion Biomedica Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Angion Biomedica Ischemia Reperfusion Injury Product Portfolio
  6. 8.1.5 Angion Biomedica Recent Developments
  7. 8.2 Catalyst Biosciences
  8. 8.2.1 Catalyst Biosciences Company Information
  9. 8.2.2 Catalyst Biosciences Business Overview
  10. 8.2.3 Catalyst Biosciences Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Catalyst Biosciences Ischemia Reperfusion Injury Product Portfolio
  12. 8.2.5 Catalyst Biosciences Recent Developments
  13. 8.3 Ischemix Inc
  14. 8.3.1 Ischemix Inc Company Information
  15. 8.3.2 Ischemix Inc Business Overview
  16. 8.3.3 Ischemix Inc Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Ischemix Inc Ischemia Reperfusion Injury Product Portfolio
  18. 8.3.5 Ischemix Inc Recent Developments
  19. 8.4 Opsona Therapeutics
  20. 8.4.1 Opsona Therapeutics Company Information
  21. 8.4.2 Opsona Therapeutics Business Overview
  22. 8.4.3 Opsona Therapeutics Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Opsona Therapeutics Ischemia Reperfusion Injury Product Portfolio
  24. 8.4.5 Opsona Therapeutics Recent Developments
  25. 8.5 Pharming
  26. 8.5.1 Pharming Company Information
  27. 8.5.2 Pharming Business Overview
  28. 8.5.3 Pharming Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pharming Ischemia Reperfusion Injury Product Portfolio
  30. 8.5.5 Pharming Recent Developments
  31. 8.6 TheraSource
  32. 8.6.1 TheraSource Company Information
  33. 8.6.2 TheraSource Business Overview
  34. 8.6.3 TheraSource Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  35. 8.6.4 TheraSource Ischemia Reperfusion Injury Product Portfolio
  36. 8.6.5 TheraSource Recent Developments
  37. 8.7 Bolder Biotechnology
  38. 8.7.1 Bolder Biotechnology Company Information
  39. 8.7.2 Bolder Biotechnology Business Overview
  40. 8.7.3 Bolder Biotechnology Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bolder Biotechnology Ischemia Reperfusion Injury Product Portfolio
  42. 8.7.5 Bolder Biotechnology Recent Developments
  43. 8.8 Corline Biomedical
  44. 8.8.1 Corline Biomedical Company Information
  45. 8.8.2 Corline Biomedical Business Overview
  46. 8.8.3 Corline Biomedical Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Corline Biomedical Ischemia Reperfusion Injury Product Portfolio
  48. 8.8.5 Corline Biomedical Recent Developments
  49. 8.9 Mifcortx
  50. 8.9.1 Mifcortx Company Information
  51. 8.9.2 Mifcortx Business Overview
  52. 8.9.3 Mifcortx Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Mifcortx Ischemia Reperfusion Injury Product Portfolio
  54. 8.9.5 Mifcortx Recent Developments
  55. 8.10 Balmes Transplantation
  56. 8.10.1 Balmes Transplantation Company Information
  57. 8.10.2 Balmes Transplantation Business Overview
  58. 8.10.3 Balmes Transplantation Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Balmes Transplantation Ischemia Reperfusion Injury Product Portfolio
  60. 8.10.5 Balmes Transplantation Recent Developments
  61. 8.11 NovelMed Therapeutics
  62. 8.11.1 NovelMed Therapeutics Company Information
  63. 8.11.2 NovelMed Therapeutics Business Overview
  64. 8.11.3 NovelMed Therapeutics Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  65. 8.11.4 NovelMed Therapeutics Ischemia Reperfusion Injury Product Portfolio
  66. 8.11.5 NovelMed Therapeutics Recent Developments
  67. 8.12 Hope Pharmaceuticals
  68. 8.12.1 Hope Pharmaceuticals Company Information
  69. 8.12.2 Hope Pharmaceuticals Business Overview
  70. 8.12.3 Hope Pharmaceuticals Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Hope Pharmaceuticals Ischemia Reperfusion Injury Product Portfolio
  72. 8.12.5 Hope Pharmaceuticals Recent Developments
  73. 8.13 Omeros Corp
  74. 8.13.1 Omeros Corp Company Information
  75. 8.13.2 Omeros Corp Business Overview
  76. 8.13.3 Omeros Corp Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Omeros Corp Ischemia Reperfusion Injury Product Portfolio
  78. 8.13.5 Omeros Corp Recent Developments
  79. 8.14 Prothix
  80. 8.14.1 Prothix Company Information
  81. 8.14.2 Prothix Business Overview
  82. 8.14.3 Prothix Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Prothix Ischemia Reperfusion Injury Product Portfolio
  84. 8.14.5 Prothix Recent Developments
  85. 8.15 SBI Pharmaceuticals
  86. 8.15.1 SBI Pharmaceuticals Company Information
  87. 8.15.2 SBI Pharmaceuticals Business Overview
  88. 8.15.3 SBI Pharmaceuticals Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  89. 8.15.4 SBI Pharmaceuticals Ischemia Reperfusion Injury Product Portfolio
  90. 8.15.5 SBI Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst